Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.55 |
| ▸ | LSS | P48449 | 2/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015669 | 0.90 | F10 (0.64) | F10LSSITGB3ITGA2BCHRM1 | |
| SCHEMBL6787217 | 0.79 | F10 (0.68) | F10LSSUSP2LMNATSHR | |
| SCHEMBL1387210 | 0.77 | F10 (0.82) | F10LSSUSP2LMNATSHR | |
| SCHEMBL6792487 | 0.77 | F10 (0.70) | F10LSSITGB3ITGA2BUSP2 | |
| SCHEMBL6180649 | 0.75 | RAB9A (0.46) | LMNATSHRMAPT | |
| SCHEMBL1387222 | 0.75 | TSHR (0.76) | F10LSSUSP2LMNATSHR | |
| SCHEMBL7922292 | 0.75 | F10 (0.47) | F10LSSMAPT | |
| SCHEMBL6792503 | 0.74 | F10 (0.51) | F10LSSUSP2LMNATSHR | |
| SCHEMBL6798769 | 0.74 | F10 (0.76) | F10LSSUSP2LMNATSHR | |
| SCHEMBL6790771 | 0.73 | F10 (0.73) | F10LSSUSP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0844877-B1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ASTRAZENECA AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| US-6090813-A | Use of oxido-squalene cyclase inhibitors to lower blood cholesterol | ZENECA LIMITED (GB) | 2000-07-18 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| CN-1164232-A | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LTD (GB) | 1997-11-05 | — | — | CN | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | F10 35/4885LSS 1192/4885ITGB3 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.